# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
According to a recent report by Pablo Zuanic of Zuanic & Associates, MariMed (OTC: MRMD) a multi-state cannabis operator (M...
Cannabis equity analysts may need to revise their 2024 earnings estimates after first-quarter results from major multi-state op...
In our January 2024 outlook, we asserted that cannabis equity analysts, having been burned by the need for continual downward r...
MariMed (OTC:MRMD) reported quarterly sales of $37.933 million which beat the analyst consensus estimate of $36.950 million by ...